stockrowDanaher Corporation
DHR Healthcare Diagnostics & Research
Danaher Corporation’s revenue for fiscal 2025 (year ended December 2025) was $24.6 billion, up 2.90% from fiscal 2024.
- Revenue
- +8.28%
- EPS
- +36.7%
- Free cash flow
- +19.1%
- Total debt
- +44.9%
Quarter to September 2026, against a year earlier
Follow DHR
Alert me
Danaher Corporation (DHR) EPS (diluted)
Danaher Corporation's EPS (diluted) for fiscal 2025 was $5.05, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $6.11. Over the past ten years it has ranged from $3.53 (fiscal 2017) to $9.66 (fiscal 2022); the current reading is higher than 64% of that period. EPS (diluted) has fallen for 3 consecutive fiscal years. Danaher Corporation ranks 8th of 49 Diagnostics & Research companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $5.05 | (4.54%) |
| FY2024 | $5.29 | (17.08%) |
| FY2023 | $6.38 | (33.95%) |
| FY2022 | $9.66 | 12.20% |
| FY2021 | $8.61 | 76.07% |
| FY2020 | $4.89 | 20.74% |
| FY2019 | $4.05 | 8.29% |
| FY2018 | $3.74 | 5.95% |
| FY2017 | $3.53 | (3.29%) |
| FY2016 | $3.65 | (23.00%) |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $1.75 | 42.28% |
| Jun 2026 | $1.23 | (15.17%) |
| Mar 2026 | $1.45 | (13.69%) |
| Dec 2025 | $1.68 | 32.28% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| MTD Mettler-Toledo International, Inc. compare | $46.15 |
| TMO Thermo Fisher Scientific Inc. compare | $18.96 |
| IDXX IDEXX Laboratories, Inc. compare | $14.83 |
| IQV IQVIA Holdings Inc. compare | $8.24 |
| DHR Danaher Corporation | $6.11 |
| ILMN Illumina, Inc. compare | $5.81 |
| A Agilent Technologies, Inc. compare | $5.08 |
| WAT Waters Corporation compare | $2.33 |
| NTRA Natera, Inc. compare | −$1.14 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on DHR
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement